{
 "query": "emtricitabine / tenofovir disoproxil",
 "ingredient": "emtricitabine / tenofovir disoproxil",
 "slug": "emtricitabine-tenofovir-disoproxil",
 "rxcui": "1008145",
 "brands": [
  "Truvada"
 ],
 "names": [
  "emtricitabine / tenofovir disoproxil"
 ],
 "components": [
  {
   "ingredient": "emtricitabine",
   "slug": "emtricitabine",
   "grade": "B",
   "total": 82,
   "scores": {
    "safety": "C",
    "evidence": "C",
    "regulatory": "A",
    "conflict": "A",
    "options": "A"
   },
   "boxed": true,
   "controlled": false,
   "first_approval_fmt": "07/02/2003",
   "first_approval": "20030702"
  },
  {
   "ingredient": "tenofovir disoproxil",
   "slug": "tenofovir-disoproxil",
   "grade": "B",
   "total": 79,
   "scores": {
    "safety": "C",
    "evidence": "D",
    "regulatory": "A",
    "conflict": "A",
    "options": "A"
   },
   "boxed": true,
   "controlled": false,
   "first_approval_fmt": "10/26/2001",
   "first_approval": "20011026"
  }
 ],
 "classes": [],
 "alternatives": [],
 "label": {},
 "faers": null,
 "faers_base": {
  "total": 20692304,
  "serious_share": 0.5742697381596559,
  "death_share": 0.09102355155810585
 },
 "recalls": [],
 "recall_total": 0,
 "drugsfda": {
  "first_approval": "20011026",
  "first_approval_fmt": "",
  "anda": 2,
  "nda": 0,
  "rems": false,
  "labeling_recent": 0
 },
 "trials": null,
 "pubmed": null,
 "payments": {
  "year": "2024",
  "usd": 0.0,
  "records": 0,
  "by_name": [],
  "names_checked": [
   "emtricitabine / tenofovir disoproxil",
   "Truvada"
  ],
  "source": "bulk-index"
 },
 "partd": null,
 "mdl": [],
 "dsc": [],
 "settlements": [],
 "prescrire": null,
 "eml": null,
 "exposure": null,
 "scores": {
  "safety": {
   "score": 70,
   "letter": "C",
   "why": [
    "Graded by its riskiest ingredient, emtricitabine (70)",
    "Carries an FDA boxed warning, the strongest warning the FDA issues (-30)",
    "Death share in reports is near or below the FAERS average (1.3x)"
   ],
   "weight": 0.35
  },
  "evidence": {
   "score": 61,
   "letter": "D",
   "why": [
    "Graded by its riskiest ingredient, tenofovir disoproxil (61)",
    "237 randomized trials and 33 systematic reviews/meta-analyses indexed in PubMed",
    "On the WHO Model List of Essential Medicines (shown for context; no score effect)",
    "No Cochrane review found (-5)",
    "Only 49% of completed registered trials posted results (-8)"
   ],
   "weight": 0.25
  },
  "regulatory": {
   "score": 95,
   "letter": "A",
   "why": [
    "Graded by its riskiest ingredient, emtricitabine (95)",
    "No recalls on record since 2016",
    "Label lists recent major changes to warnings or indications (-5)"
   ],
   "weight": 0.15
  },
  "conflict": {
   "score": 100,
   "letter": "A",
   "why": [
    "Graded by its riskiest ingredient, emtricitabine (100)",
    "Pharma paid doctors $0 tied to this drug last year: negligible",
    "Not named in any pending federal MDL"
   ],
   "weight": 0.15
  },
  "options": {
   "score": 100,
   "letter": "A",
   "why": [
    "Graded by its riskiest ingredient, emtricitabine (100)",
    "Generic versions approved (2 applications)",
    "11 same-class alternatives exist"
   ],
   "weight": 0.1
  }
 },
 "total": 79,
 "grade": "B",
 "questions": [
  "This is a fixed combination of emtricitabine and tenofovir disoproxil. Why both together, instead of only the one I need?",
  "This drug carries a boxed warning. Which specific risk does it cover, and does it apply to me?",
  "The most-reported problems in FDA's adverse event data are foetal exposure during pregnancy, drug interaction, drug resistance, anxiety. How would we recognize and handle those?",
  "Why this one over abacavir, adefovir dipivoxil, didanosine? What would make you pick one of those instead?",
  "What result are we expecting, by when, and what is the plan if it does not happen?",
  "If 100 people like me took this drug, how many would actually get better because of it, and how many would be harmed by it? (Doctors call these the number needed to treat and the number needed to harm.)",
  "The most-reported problems in FDA's adverse event data are bone density decreased, renal injury, skeletal injury, chronic kidney disease. How would we recognize and handle those?"
 ]
}